Home › Non-Hodgkin Lymphoma › Tennessee
Non-Hodgkin Lymphoma clinical trials in Tennessee
24 studies for Non-Hodgkin Lymphoma are looking for participants at sites in Tennessee.
Cities in Tennessee
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07763210A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07519772A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07082803A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Research Site, Franklin
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07123454Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- St. Jude Childrens Research Hospital, Memphis
- Vanderbilt University, Nashville
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.